reports grants from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Genzyme/Sanofi, Lilly, Otsuka and Boehringer Ingelheim
It does not compete directly on maximum weight loss with injectable multi-receptor agonists but instead offers a differentiated value proposition based on oral convenience, no restrictions, lower manufacturing costs, and the potential to dramatically expand the addressable patient population for GLP-1 therapy
As an expert in bioidentical hormone replacement therapy, Dr
For some, the medications dont just reduce hunger
Eur J Biochem 1992
Two oral GLP-1s on the US market within three months of each other, a European recommendation in May, and a pipeline of competitors moving fast behind them